Q-omics provides the consensus-scored SIGMAR1 profile across patient tissues and cancer cell-line models. SIGMAR1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SIGMAR1 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, SIGMAR1 RNA expression shows 18,634 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight OV, COAD, and ACC as cancer lineages where SIGMAR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIGMAR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIGMAR1 survival associations across molecular data types. SIGMAR1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIGMAR1 RNA expression–survival associations across cancer types. High SIGMAR1 expression shows unfavorable associations in BLCA, SKCM, KIRP, ACC and KICH, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for SIGMAR1 RNA expression.
This table summarizes SIGMAR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SIGMAR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIGMAR1 shows higher tumor expression in COAD, HNSC, KIRP, BLCA, LUAD and LUSC. The COAD box plot shows higher SIGMAR1 RNA expression in tumor versus normal tissue (log2 FC = +1.740, t-test p < 0.001).
This table shows molecular features associated with SIGMAR1 in patient tissues and cancer cell lines. In patient samples, SIGMAR1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIGMAR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
